{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:47:34Z","timestamp":1787028454090,"version":"build-2736575974"},"reference-count":223,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Viral-associated respiratory infectious diseases are one of the most prominent subsets of respiratory failures, known as viral respiratory infections (VRI). VRIs are proceeded by an infection caused by viruses infecting the respiratory system. For the past 100 years, viral associated respiratory epidemics have been the most common cause of infectious disease worldwide. Due to several drawbacks of the current anti-viral treatments, such as drug resistance generation and non-targeting of viral proteins, the development of novel nanotherapeutic or nano-vaccine strategies can be considered essential. Due to their specific physical and biological properties, nanoparticles hold promising opportunities for both anti-viral treatments and vaccines against viral infections. Besides the specific physiological properties of the respiratory system, there is a significant demand for utilizing nano-designs in the production of vaccines or antiviral agents for airway-localized administration. SARS-CoV-2, as an immediate example of respiratory viruses, is an enveloped, positive-sense, single-stranded RNA virus belonging to the coronaviridae family. COVID-19 can lead to acute respiratory distress syndrome, similarly to other members of the coronaviridae. Hence, reviewing the current and past emerging nanotechnology-based medications on similar respiratory viral diseases can identify pathways towards generating novel SARS-CoV-2 nanotherapeutics and\/or nano-vaccines.<\/jats:p>","DOI":"10.3390\/ijms22136937","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T11:45:40Z","timestamp":1624880740000},"page":"6937","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID)"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-2396","authenticated-orcid":false,"given":"Amir","family":"Seyfoori","sequence":"first","affiliation":[{"name":"Laboratory for Innovations in Micro Engineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada"},{"name":"Biomaterials and Tissue Engineering Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5197-1139","authenticated-orcid":false,"given":"Mahdieh","family":"Shokrollahi Barough","sequence":"additional","affiliation":[{"name":"Department of Immunology, Iran University of Medical Sciences, Tehran 1449614535, Iran"},{"name":"ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-0473","authenticated-orcid":false,"given":"Pooneh","family":"Mokarram","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran"},{"name":"Autophagy Research Center, Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-170X","authenticated-orcid":false,"given":"Mazaher","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan 6517838695, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvaneh","family":"Mehrbod","sequence":"additional","affiliation":[{"name":"Influenza and Respiratory Viruses Department, Pasteur Institute of IRAN, Tehran 1316943551, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Sheidary","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155-6451, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6876-7633","authenticated-orcid":false,"given":"Tayyebeh","family":"Madrakian","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan 6517838695, Iran"},{"name":"Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155-6451, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kiumarsi","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Cell Science, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavia","family":"Walsh","sequence":"additional","affiliation":[{"name":"Laboratory for Innovations in Micro Engineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kielan D.","family":"McAlinden","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, School of Health Sciences, University of Tasmania, Launceston, TAS 7248, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra C.","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Roger Williams Medical Center, Immuno-Oncology Institute (Ix2), Providence, RI 02908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-2306","authenticated-orcid":false,"given":"Pawan","family":"Sharma","sequence":"additional","affiliation":[{"name":"Center for Translational Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Jane & Leonard Korman Respiratory Institute, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Zeki","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, U.C. Davis Lung Center, Davis School of Medicine, University of California, Davis, CA 95817, USA"},{"name":"Veterans Affairs Medical Center, Mather, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-508X","authenticated-orcid":false,"given":"Saeid","family":"Ghavami","sequence":"additional","affiliation":[{"name":"Autophagy Research Center, Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran"},{"name":"Department of Human Anatomy and Cell Science, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"},{"name":"Biology of Breathing Theme, Children Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"},{"name":"Research Institute of Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-6557","authenticated-orcid":false,"given":"Mohsen","family":"Akbari","sequence":"additional","affiliation":[{"name":"Laboratory for Innovations in Micro Engineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada"},{"name":"Biotechnology Center, Silesian University of Technology, Akademicka 2A, 44-100 Gliwice, Poland"},{"name":"Center for Advanced Materials and Related Technologies, University of Victoria, Victoria, BC V8P 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","article-title":"World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"Sohrabi","year":"2020","journal-title":"Int. J. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"van Doorn, H.R., and Yu, H. (2020). Viral Respiratory Infections. Hunt. Trop. Med. Emerg. Infect. Dis., 284\u2013288.","DOI":"10.1016\/B978-0-323-55512-8.00033-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1128\/JVI.02677-05","article-title":"Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells","volume":"80","author":"Ibricevic","year":"2006","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173288","DOI":"10.1016\/j.ejphar.2020.173288","article-title":"Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?","volume":"882","author":"Sureda","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","article-title":"A Review of Coronavirus Disease-2019 (COVID-19)","volume":"87","author":"Singhal","year":"2020","journal-title":"Indian J. Pediatrics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00281-016-0558-0","article-title":"The host immune response in respiratory virus infection: Balancing virus clearance and immunopathology","volume":"38","author":"Newton","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_8","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: What does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/21505594.2020.1780088","article-title":"Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway","volume":"11","author":"Shojaei","year":"2020","journal-title":"Virulence"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"110924","DOI":"10.1016\/j.msec.2020.110924","article-title":"An overview of functional nanoparticles as novel emerging antiviral therapeutic agents","volume":"112","author":"Chen","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"118524","DOI":"10.1016\/j.ijpharm.2019.118524","article-title":"Pulmonary delivery of nanocomposite microparticles (NCMPS) incorporating mir-146a for treatment of COPD","volume":"569","author":"Mohamed","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.2174\/1381612823666171004120544","article-title":"Overview on Inhalable Nanocarriers for Respiratory Immunization","volume":"23","author":"Ferreira","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/088282403322396091","article-title":"Upper Respiratory Tract Immunity","volume":"16","author":"Zuercher","year":"2003","journal-title":"Viral Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1743-422X-10-305","article-title":"Human rhinoviruses and enteroviruses in influenza-like illness in Latin America","volume":"10","author":"Garcia","year":"2013","journal-title":"Virol. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","article-title":"The disease burden of influenza beyond respiratory illness","volume":"39","author":"Macias","year":"2021","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11908-005-0036-7","article-title":"Human metapneumovirus: An important cause of respiratory disease in children and adults","volume":"7","author":"Williams","year":"2005","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1055\/s-0036-1584798","article-title":"Parainfluenza Virus Infection","volume":"37","author":"Branche","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Meng, J., Stobart, C.C., Hotard, A.L., and Moore, M.L. (2014). An overview of respiratory syncytial virus. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004016"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/br.28.4.409-422.1964","article-title":"Rhinoviruses and Respiratory Disease","volume":"28","author":"Gwaltney","year":"1964","journal-title":"Bacteriol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/ncomms6205","article-title":"Nasal immunity is an ancient arm of the mucosal immune system of vertebrates","volume":"5","author":"Tacchi","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_23","first-page":"3","article-title":"Human nasal immune system: A special site for immune response establishment","volume":"32","author":"Porzia","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaci.2017.07.018","article-title":"Propagation of respiratory viruses in human airway epithelia reveals persistent virus-specific signatures","volume":"141","author":"Brito","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3109\/10717544.2014.920431","article-title":"Nasal-nanotechnology: Revolution for efficient therapeutics delivery","volume":"23","author":"Kumar","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.it.2017.08.005","article-title":"Tissue-Specific Immunity at the Oral Mucosal Barrier","volume":"39","author":"Moutsopoulos","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oooo.2013.07.013","article-title":"Oral mucosal immunity","volume":"116","author":"Feller","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Osorio, R., Alfonso-Rodr\u00edguez, C.A., Medina-Castillo, A.L., Alaminos, M., and Toledano, M. (2016). Bioactive Polymeric Nanoparticles for Periodontal Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166217"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/prd.12112","article-title":"Saliva and viral infections","volume":"70","author":"Corstjens","year":"2016","journal-title":"Periodontology 2000"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1128\/JVI.01363-09","article-title":"Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease","volume":"83","author":"Meyerholz","year":"2009","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ortega, M., Guzm\u00e1n Merino, A., Fraile-Mart\u00ednez, O., Recio-Ruiz, J., Pekarek, L., Guijarro, L.G., Garc\u00eda-Honduvilla, N., \u00c1lvarez-Mon, M., Buj\u00e1n, J., and Garc\u00eda-Gallego, S. (2020). Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090874"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/1947-2714.118923","article-title":"Langerhans cells and their role in oral mucosal diseases","volume":"5","author":"Upadhyay","year":"2013","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcimb.2013.00013","article-title":"Vaccine delivery using nanoparticles","volume":"3","author":"Gregory","year":"2013","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.peptides.2017.07.013","article-title":"Cathelicidins display conserved direct antiviral activity towards rhinovirus","volume":"95","author":"Sousa","year":"2017","journal-title":"Peptides"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1099\/vir.0.045013-0","article-title":"The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins","volume":"94 Pt 1","author":"Tripathi","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0006-291X(91)91350-L","article-title":"Complementary DNA sequence of rabbit CAP18\u2014A unique lipopolysaccharide binding protein","volume":"179","author":"Larrick","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00784-017-2172-5","article-title":"The effect of saliva on the fate of nanoparticles","volume":"22","author":"Teubl","year":"2018","journal-title":"Clin. Oral Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12951-019-0566-z","article-title":"Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: Current status and potential future applications","volume":"18","author":"Wnorowska","year":"2020","journal-title":"J. NanobioTechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1038\/jid.2009.120","article-title":"Ceragenins: A class of antiviral compounds to treat orthopox infections","volume":"129","author":"Howell","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41598-017-04653-1","article-title":"Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13","volume":"7","author":"Niemirowicz","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.4049\/jimmunol.1700706","article-title":"Carbon Nanoparticles Inhibit the Antimicrobial Activities of the Human Cathelicidin LL-37 through Structural Alteration","volume":"199","author":"Findlay","year":"2017","journal-title":"J. Immunol. (Baltim. Md. 1950)"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fimmu.2020.00085","article-title":"Citrullination Alters the Antiviral and Immunomodulatory Activities of the Human Cathelicidin LL-37 During Rhinovirus Infection","volume":"11","author":"Casanova","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Roth, A., L\u00fctke, S., Meinberger, D., Hermes, G., Sengle, G., Koch, M., Streichert, T., and Klatt, A.R. (2020). LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro. bioRxiv.","DOI":"10.1101\/2020.12.02.408153"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fpubh.2020.00232","article-title":"Vitamin D Deficiency and Air Pollution Exacerbate COVID-19 through Suppression of Antiviral Peptide LL37","volume":"8","author":"Clem","year":"2020","journal-title":"Front. Public Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12951-017-0278-1","article-title":"Comparative efficacy analysis of anti-microbial peptides, LL-37 and indolicidin upon conjugation with CNT, in human monocytes","volume":"15","author":"Pradhan","year":"2017","journal-title":"J. NanobioTechnol."},{"key":"ref_46","first-page":"e811","article-title":"Implications of scavenger receptors in the safe development of nanotherapeutics","volume":"2","author":"Shannahan","year":"2015","journal-title":"Recept. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ACI.0000000000000031","article-title":"Engineered nanomaterial exposure and the risk of allergic disease","volume":"14","author":"Shannahan","year":"2014","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1289\/ehp.8455327","article-title":"The alveolar macrophage","volume":"55","author":"Bowden","year":"1984","journal-title":"Environ. Health Perspect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27141","DOI":"10.1073\/pnas.2014352117","article-title":"Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines","volume":"117","author":"Rao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wiley, J.A., Richert, L.E., Swain, S.D., Harmsen, A., Barnard, D.L., Randall, T.D., Jutila, M., Douglas, T., Broomell, C., and Young, M. (2009). Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007142"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fimmu.2016.00258","article-title":"Inducible Bronchus-Associated Lymphoid Tissue: Taming Inflammation in the Lung","volume":"7","author":"Hwang","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nnano.2014.17","article-title":"Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils","volume":"9","author":"Wang","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cmdc.200900049","article-title":"Further evidence of the anti-inflammatory effects of silver nanoparticles","volume":"4","author":"Wong","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12011-014-0113-6","article-title":"Zinc oxide nanoparticles reduce apoptosis and oxidative stress values in isolated rat pancreatic islets","volume":"162","author":"Rahimifard","year":"2014","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.micinf.2011.08.019","article-title":"Surfactant and its role in the pathobiology of pulmonary infection","volume":"14","author":"Glasser","year":"2012","journal-title":"Microbes Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2010.11.009","article-title":"Lung surfactant DPPG phospholipid inhibits vaccinia virus infection","volume":"89","author":"Perino","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1128\/JVI.77.8.4858-4866.2003","article-title":"Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry","volume":"77","author":"Balakireva","year":"2003","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/cc4851","article-title":"Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: Results of a meta-analysis","volume":"10","author":"Davidson","year":"2006","journal-title":"Crit. Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"25488","DOI":"10.1074\/jbc.M109.040832","article-title":"Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2","volume":"284","author":"Kuronuma","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0095-5108(18)30376-2","article-title":"Clinical Trials of Synthetic Surfactant in the Respiratory Distress Syndrome of Premature Infants","volume":"20","author":"Corbet","year":"1993","journal-title":"Clin. Perinatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J. Pharm Anal."},{"key":"ref_62","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1183\/09031936.01.00228801","article-title":"Lung mucosal immunity: Immunoglobulin-A revisited","volume":"18","author":"Pilette","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20401","DOI":"10.3402\/jom.v5i0.20401","article-title":"Secretory immunity with special reference to the oral cavity","volume":"5","author":"Brandtzaeg","year":"2013","journal-title":"J. Oral Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"ftv121","DOI":"10.1093\/femspd\/ftv121","article-title":"IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates","volume":"74","author":"Lanka","year":"2016","journal-title":"Pathog. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/02652048.2012.726279","article-title":"Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens","volume":"30","author":"Sharma","year":"2013","journal-title":"J. Microencapsul."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jorquera, P.A., and Tripp, R.A. (2016). Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines, 4.","DOI":"10.3390\/vaccines4040045"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, M.C. (2018). Sol-gel Silica Nanoparticles in Medicine: A Natural Choice. Design, Synthesis and Products. Molecules, 23.","DOI":"10.3390\/molecules23082021"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Heida, R., Hinrichs, W.L., and Frijlink, H.W. (2021). Inhaled vaccine delivery in the combat against respiratory viruses: A 2021 overview of recent developments and implications for COVID-19. Expert Rev. Vaccines.","DOI":"10.1080\/14760584.2021.1903878"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.2147\/IJN.S110796","article-title":"Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response","volume":"11","author":"Song","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1021\/nn302538y","article-title":"Hyaluronic Acid\u2013Gold Nanoparticle\/Interferon \u03b1 Complex for Targeted Treatment of Hepatitis C Virus Infection","volume":"6","author":"Lee","year":"2012","journal-title":"ACS Nano"},{"key":"ref_72","first-page":"1","article-title":"Nanoparticle-based vaccines against respiratory viruses","volume":"10","author":"Gauthier","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1002\/jcp.28120","article-title":"Nanovaccine: A novel approach in immunization","volume":"234","author":"Darroudi","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_74","first-page":"101","article-title":"Nanovaccines-an overview","volume":"1","author":"Saluja","year":"2011","journal-title":"Int. J. Pharm. Front. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2016-0068","article-title":"Intranasal delivery of nanoparticle-based vaccines","volume":"8","author":"Marasini","year":"2017","journal-title":"Ther. Deliv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1039\/a907827d","article-title":"NanobioTechnology and its role in the development of new analytical devices","volume":"125","author":"Laval","year":"2000","journal-title":"Analyst"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.0712144105","article-title":"Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2","volume":"105","author":"Utley","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1742-1241.1997.tb09640.x","article-title":"Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years","volume":"51","author":"Daubeney","year":"1997","journal-title":"Br. J. Clin. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gomes, A.C., Mohsen, M., and Bachmann, M.F. (2017). Harnessing nanoparticles for immunomodulation and vaccines. Vaccines, 5.","DOI":"10.3390\/vaccines5010006"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2005.10.008","article-title":"Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip\u00ae","volume":"24","author":"Delore","year":"2006","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"818","DOI":"10.15585\/mmwr.mm6430a3","article-title":"Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015\u20132016 influenza season","volume":"64","author":"Grohskopf","year":"2015","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","article-title":"Live attenuated influenza vaccine (FluMist\u00ae; Fluenz\u2122)","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2011.04.119","article-title":"A pandemic influenza vaccine in India: From strain to sale within 12 months","volume":"29","author":"Dhere","year":"2011","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1073\/pnas.1422923112","article-title":"Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization","volume":"112","author":"Fromen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.biomaterials.2014.10.043","article-title":"Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response","volume":"37","author":"Rahimian","year":"2015","journal-title":"Biomaterials"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","article-title":"Nanoparticles for the induction of antigen-specific immunological tolerance","volume":"9","author":"Kishimoto","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2017.01.021","article-title":"Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses","volume":"141","author":"Tao","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., and Du, L. (2020). Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol. Immunol., in press.","DOI":"10.1038\/s41423-020-0400-4"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jmv.25736","article-title":"Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach","volume":"92","author":"Bhattacharya","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1750-2659.2011.00271.x","article-title":"The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine","volume":"6","author":"Svindland","year":"2012","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_92","unstructured":"Medepalli, K.K. (2008). Advanced Nanomaterials for Biomedical Applications, University of Louisville."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: Classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1166\/jnn.2014.9080","article-title":"Liposomes: Versatile and biocompatible nanovesicles for efficient biomolecules delivery","volume":"14","author":"Mallick","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.04.036","article-title":"Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens","volume":"364","author":"Perrie","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Nikitina, E., Larionova, I., Choinzonov, E., and Kzhyshkowska, J. (2018). Monocytes and macrophages as viral targets and reservoirs. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092821"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.025","article-title":"Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization","volume":"303","author":"Wang","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.05.019","article-title":"The vesicle size of DDA: TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production","volume":"154","author":"Devitt","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_101","unstructured":"(2021, June 27). Molecular Depot. Pfizer-BioNTech Moderna and Janssen Vaccines USA: Molecular Depot 2021. Available online: https:\/\/moleculardepot.com\/2020\/12\/23\/pfizer-biontech-and-moderna-covid-19-vaccines-comparison\/."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ulery, B.D., Kumar, D., Ramer-Tait, A.E., Metzger, D.W., Wannemuehler, M.J., and Narasimhan, B. (2011). Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017642"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s11095-008-9800-3","article-title":"Methods for the preparation and manufacture of polymeric nanoparticles","volume":"26","author":"Vauthier","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0166-3542(92)90058-D","article-title":"Drug targeting systems for antiviral agents: Options and limitations","volume":"18","author":"Meijer","year":"1992","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"120597","DOI":"10.1016\/j.biomaterials.2020.120597","article-title":"Polymeric nanoparticle vaccines to combat emerging and pandemic threats","volume":"268","author":"Wibowo","year":"2021","journal-title":"Biomaterials"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jphp.13021","article-title":"Self-emulsifying drug delivery systems and cationic surfactants: Do they potentiate each other in cytotoxicity?","volume":"71","author":"Lam","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"114297","DOI":"10.1016\/j.envpol.2020.114297","article-title":"Polystyrene nanoparticles: Sources, occurrence in the environment, distribution in tissues, accumulation and toxicity to various organisms","volume":"262","author":"Kik","year":"2020","journal-title":"Environ. Pollut."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1016\/j.vaccine.2015.07.100","article-title":"Polymeric micro\/nanoparticles: Particle design and potential vaccine delivery applications","volume":"33","author":"Yue","year":"2015","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s11095-006-9101-7","article-title":"Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV\/AIDS","volume":"23","author":"Shah","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1039\/c3tb20191k","article-title":"Polymeric theranostics: Using polymer-based systems for simultaneous imaging and therapy","volume":"1","author":"Georgiou","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.progpolymsci.2016.05.005","article-title":"Polymeric nanostructured materials for biomedical applications","volume":"60","author":"Tang","year":"2016","journal-title":"Prog. Polym. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1208\/s12248-014-9699-z","article-title":"Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles","volume":"17","author":"Goodman","year":"2015","journal-title":"AAPS J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1016\/j.actbio.2010.01.040","article-title":"Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens","volume":"6","author":"Schiltz","year":"2010","journal-title":"Acta Biomater."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/mp2004059","article-title":"Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen","volume":"9","author":"Petersen","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep00198","article-title":"Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants","volume":"1","author":"Ulery","year":"2011","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/adhm.201300525","article-title":"Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours","volume":"3","author":"Ross","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","article-title":"PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect","volume":"63","author":"Acharya","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","article-title":"PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity","volume":"12","author":"Silva","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","article-title":"Harnessing nanoparticles for immune modulation","volume":"36","author":"Getts","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Mansoor, F., Earley, B., Cassidy, J.P., Markey, B., Doherty, S., and Welsh, M.D. (2015). Comparing the immune response to a novel intranasal nanoparticle PLA vaccine and a commercial BPI3V vaccine in dairy calves. BMC Vet. Res., 11.","DOI":"10.1186\/s12917-015-0481-y"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2016.12.039","article-title":"Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs","volume":"247","author":"Dhakal","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1016\/j.vaccine.2009.07.037","article-title":"Poly (\u03b3-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice","volume":"27","author":"Okamoto","year":"2009","journal-title":"Vaccine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3389\/fimmu.2018.00934","article-title":"Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs","volume":"9","author":"Dhakal","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/jmv.24253","article-title":"Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration","volume":"87","author":"Liu","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1038\/s41598-018-21292-2","article-title":"Efficacy of mucosal polyanhydride nanovaccine against Respiratory Syncytial Virus infection in the neonatal calf","volume":"8","author":"McGill","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41598-020-57608-4","article-title":"Antiviral potential of 3\u2019-sialyllactose- and 6\u2019-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses","volume":"10","author":"Gunther","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jmv.25928","article-title":"A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus","volume":"92","author":"Kandeel","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Khaitov, M., Nikonova, A., Shilovskiy, I., Kozhikhova, K., Kofiadi, I., Vishnyakova, L., Nikolskii, A., Gattinger, P., Kovchina, V., and Barvinskaia, E. (2021). Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy.","DOI":"10.22541\/au.161359798.81563481\/v1"},{"key":"ref_130","unstructured":"Paull, J.R., Castellarnau, A., Luscombe, C.A., Fairley, J.K., and Heery, G.P. (2020). Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro. Biorxiv."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Zhang, L.-J., Wang, S., Xia, L., Lv, C., Tang, H.-W., Liang, Z., Xiao, G., and Pang, D.-W. (2020). Lipid-specific labeling of enveloped viruses with quantum dots for single-virus tracking. mBio, 11.","DOI":"10.1128\/mBio.00135-20"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcis.2019.02.010","article-title":"Benzoxazine monomer derived carbon dots as a broad-spectrum agent to block viral infectivity","volume":"542","author":"Huang","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"42964","DOI":"10.1021\/acsami.9b15032","article-title":"Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus (HCoV)","volume":"11","author":"Loczechin","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/jctb.2721","article-title":"Quantitative and sensitive detection of SARS coronavirus nucleocapsid protein using quantum dots-conjugated RNA aptamer on chip","volume":"86","author":"Roh","year":"2011","journal-title":"J. Chem. Technol. Biotechnol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"012001","DOI":"10.1088\/2632-959X\/ab8075","article-title":"Organic and inorganic nanoparticle vaccines for prevention of infectious diseases","volume":"1","author":"Poon","year":"2020","journal-title":"Nano Express"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/acsami.7b16455","article-title":"meso-Tetrahydroxyphenylchlorin-conjugated gold nanoparticles as a tool to improve photodynamic therapy","volume":"10","author":"Haimov","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s11051-014-2430-2","article-title":"Porous silicon nanoparticles as scavengers of hazardous viruses","volume":"16","author":"Osminkina","year":"2014","journal-title":"J. Nanopart. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2147\/IJN.S221667","article-title":"Pre-treatment with zirconia nanoparticles reduces inflammation induced by the pathogenic H5N1 influenza virus","volume":"15","author":"Huo","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12929-019-0563-4","article-title":"Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: Another emerging application of nanomedicine","volume":"26","author":"Ghaffari","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1134\/S1995078010050174","article-title":"Interaction of titanium dioxide nanoparticles with influenza virus","volume":"5","author":"Mazurkova","year":"2010","journal-title":"Nanotechnol. Russ."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1021\/acssensors.0c01742","article-title":"Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs","volume":"5","author":"Ventura","year":"2020","journal-title":"ACS Sens."},{"key":"ref_142","first-page":"1","article-title":"Role of metallic nanoparticles in vaccinology: Implications for infectious disease vaccine development","volume":"8","author":"Kipnis","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2217\/nnm.13.58","article-title":"Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus","volume":"9","author":"Tao","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2012.04.015","article-title":"Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles","volume":"161","author":"Jazayeri","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1348-0421.12754","article-title":"Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs","volume":"64","author":"Sekimukai","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.drudis.2008.06.016","article-title":"Virus-sized vaccine delivery systems","volume":"13","author":"Scheerlinck","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_147","unstructured":"Schneider-Ohrum, K., and Ross, T. (2012). Mucosal Vaccines: Modern Concepts, Strategies, and Challenges, Springer."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4049\/jimmunol.198.Supp.225.5","article-title":"Spike nanoparticle and recombinant adenovirus 5 vaccines induce specific antibodies against the Middle East respiratory syndrome coronavirus (MERS-CoV)","volume":"198","author":"Park","year":"2017","journal-title":"J. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.bbagen.2010.03.005","article-title":"Ferritin in the field of nanodevices","volume":"1800","author":"Yamashita","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"eabf1591","DOI":"10.1126\/sciadv.abf1591","article-title":"Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates","volume":"7","author":"He","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/acsnano.0c08379","article-title":"Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates","volume":"15","author":"Kang","year":"2021","journal-title":"ACS Nano"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.nano.2013.02.009","article-title":"Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge","volume":"9","author":"Mathieu","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.nmni.2020.100786","article-title":"Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: An immunoinformatics approach","volume":"38","author":"Ghorbani","year":"2020","journal-title":"New Microbes New Infect."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1747-0285.2008.00746.x","article-title":"Peptide nanoparticles as novel immunogens: Design and analysis of a prototypic severe acute respiratory syndrome vaccine","volume":"73","author":"Pimentel","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","article-title":"Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Lee, Y., Ko, E., Lee, Y., Kim, K., Kim, M., Lee, Y., and Kang, S. (2018). Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190868"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"21877","DOI":"10.1038\/s41598-020-78656-w","article-title":"Minimal system for assembly of SARS-CoV-2 virus like particles","volume":"10","author":"Swann","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1208\/s12249-013-0058-7","article-title":"Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine","volume":"15","author":"Sawaengsak","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/1440-1681.13393","article-title":"A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion","volume":"47","author":"Tatlow","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.vaccine.2018.02.072","article-title":"Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model","volume":"36","author":"Dabaghian","year":"2018","journal-title":"Vaccine"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nbt.3371","article-title":"In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity","volume":"33","author":"Lynn","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Roux, X., Dubuquoy, C., Durand, G., Tran-Tolla, T.-L., Castagn\u00e9, N., Bernard, J., Petit-Camurdan, A., El\u00e9ou\u00ebt, J.-F., and Riffault, S. (2008). Sub-nucleocapsid nanoparticles: A nasal vaccine against Respiratory Syncytial Virus. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001766"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.nano.2016.08.006","article-title":"RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine","volume":"13","author":"Deloizy","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/JVI.01141-13","article-title":"A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2","volume":"88","author":"Raliou","year":"2014","journal-title":"J. Virol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1703207","DOI":"10.1002\/smll.201703207","article-title":"Intranasal nanovaccine confers homo- and hetero-subtypic influenza protection","volume":"14","author":"Qi","year":"2018","journal-title":"Small"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"18149","DOI":"10.1038\/s41598-020-74949-2","article-title":"A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1128\/JVI.02052-06","article-title":"Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus","volume":"81","author":"Quan","year":"2007","journal-title":"J. Virol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Kim, A.R., Lee, D.H., Lee, S.H., Rubino, I., Choi, H.J., and Quan, F.S. (2018). Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191277"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0264-410X(02)00545-5","article-title":"Intranasal vaccination with ISCOMATRIX\u00ae adjuvanted influenza vaccine","volume":"21","author":"Coulter","year":"2003","journal-title":"Vaccine"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/mi.2008.59","article-title":"Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing","volume":"1","author":"Wee","year":"2008","journal-title":"Mucosal Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/mi.2010.50","article-title":"Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic","volume":"4","author":"Tai","year":"2011","journal-title":"Mucosal Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","article-title":"Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Kim","year":"2004","journal-title":"J. Virol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jiy238","article-title":"A Lipid\/DNA adjuvant-inactivated influenza virus vaccine protects Rhesus Macaques from uncontrolled virus replication after heterosubtypic influenza A virus challenge","volume":"218","author":"Carroll","year":"2018","journal-title":"J. Infect. Dis"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","article-title":"Methods for preparation of drug-loaded polymeric nanoparticles","volume":"2","author":"Reis","year":"2006","journal-title":"Nanomedicine"},{"key":"ref_179","first-page":"265","article-title":"Nanoencapsulation for drug delivery","volume":"13","author":"Kumari","year":"2014","journal-title":"EXCLI J."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"105003","DOI":"10.1039\/C5RA19388E","article-title":"Methods and strategies for the synthesis of diverse nanoparticles and their applications: A comprehensive overview","volume":"5","author":"Dhand","year":"2015","journal-title":"RSC Adv."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Ahmadi, M., Madrakian, T., and Afkhami, A. (2020). Smart nanogels in cancer therapy. Smart Nanocontainers, Elsevier.","DOI":"10.1016\/B978-0-12-816770-0.00011-3"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/7651_2018_191","article-title":"Preparation and Characterization of Simvastatin Nanocapsules: Encapsulation of Hydrophobic Drugs in Calcium Alginate","volume":"2125","author":"Ahmadi","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/jamp.2009.0759","article-title":"Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles","volume":"23","author":"Gauss","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/bm100474w","article-title":"Antioxidant and anti-inflammatory activities of hydroxybenzyl alcohol releasing biodegradable polyoxalate nanoparticles","volume":"11","author":"Park","year":"2010","journal-title":"Biomacromolecules"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.biomaterials.2010.11.033","article-title":"Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1128\/AAC.00235-13","article-title":"Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors","volume":"57","author":"Alhajlan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.powtec.2013.01.037","article-title":"Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery","volume":"239","author":"Silva","year":"2013","journal-title":"Powder Technol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/03639045.2013.858740","article-title":"In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration","volume":"41","author":"Liu","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12931-016-0474-9","article-title":"Respiratory viral infections and host responses; insights from genomics","volume":"17","author":"Troy","year":"2016","journal-title":"Respir. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cbi.2019.05.028","article-title":"Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases","volume":"308","author":"Mehta","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_192","first-page":"131","article-title":"Inhalation drug delivery devices: Technology update","volume":"8","author":"Ibrahim","year":"2015","journal-title":"Med. Devices (Auckl.)"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/jps.22085","article-title":"In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler","volume":"99","author":"Bains","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jconrel.2011.09.089","article-title":"Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation","volume":"157","author":"Conti","year":"2012","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4155\/tde-2019-0009","article-title":"Pulmonary delivery of siRNA as a novel treatment for lung diseases","volume":"10","author":"Kandil","year":"2019","journal-title":"Ther. Deliv."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic aents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.bioconjchem.6b00370","article-title":"Thermoresponsive polymer nanoparticles co-deliver RSV F trimers with a TLR-7\/8 adjuvant","volume":"27","author":"Francica","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Chan, W.C. (2020). Nano Research for COVID-19, ACS Publications.","DOI":"10.1021\/acsnano.0c02540"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03639049309038764","article-title":"Liposomes for drug delivery to the respiratory tract","volume":"19","author":"Taylor","year":"1993","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1128\/AAC.32.6.890","article-title":"Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes","volume":"32","author":"Wyde","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_206","first-page":"8","article-title":"Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19","volume":"8","author":"Serrano","year":"2020","journal-title":"Int. J. Res. Health Sci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11095-008-9760-7","article-title":"Polymer chemistry influences monocytic uptake of polyanhydride nanospheres","volume":"26","author":"Ulery","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"An, X., Martinez-Paniagua, M., Rezvan, A., Fathi, M., Singh, S., Biswas, S., Pourpak, M., Yee, C., Liu, X., and Varadarajan, N. (2020). Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. bioRxiv.","DOI":"10.1101\/2020.07.23.212357"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1016\/j.vaccine.2009.04.074","article-title":"PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants","volume":"27","author":"Ichinohe","year":"2009","journal-title":"Vaccine"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: Potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/IAI.72.1.238-246.2004","article-title":"Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis","volume":"72","author":"Chen","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.femsim.2005.02.009","article-title":"Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis","volume":"45","author":"Giri","year":"2005","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CVI.00250-09","article-title":"Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies","volume":"17","author":"Mapletoft","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11259-011-9484-8","article-title":"Mucosal immunization provides better protection than subcutaneous immunization against Pasteurella multocida (B: 2) in mice preimmunized with the outer membrane proteins","volume":"35","author":"Kharb","year":"2011","journal-title":"Vet. Res. Commun."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"McCormick, A.A., Shakeel, A., Yi, C., Kaur, H., Mansour, A.M., and Bakshi, C.S. (2018). Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194614"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn5062029","article-title":"Nanoparticle-based immunotherapy for cancer","volume":"9","author":"Shao","year":"2015","journal-title":"ACS Nano"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.nano.2016.08.028","article-title":"Nanoparticle-based B-cell targeting vaccines: Tailoring of humoral immune responses by functionalization with different TLR-ligands","volume":"13","author":"Zilker","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1704408","DOI":"10.1002\/adma.201704408","article-title":"Antigen-Directed Fabrication of a Multifunctional Nanovaccine with Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immunotherapy","volume":"30","author":"Pan","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41423-020-0407-x","article-title":"COVID-19: A new challenge for human beings","volume":"17","author":"Yang","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_221","unstructured":"Novavax Press (2021, June 27). Novavax Press Release on 2\/26\/20. Available online: http:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-advances-developmentnovel-covid-19-vaccine."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6937\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:25:42Z","timestamp":1760163942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":223,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22136937"],"URL":"https:\/\/doi.org\/10.3390\/ijms22136937","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]}}}